Litigation Details for Amgen Inc. v. Ariad Pharmaceuticals Inc. (D. Del. 2006)

Amgen Inc. v. Ariad Pharmaceuticals Inc. (D. Del. 2006)

Docket	1:06-cv-00259	Date Filed	2006-04-20
Court	District Court, D. Delaware	Date Terminated	2010-01-04
Cause	28:2201 Declaratory Judgment	Assigned To	Mary Pat Thynge
Jury Demand	Defendant	Referred To
Patents	8,080,580
Link to Docket	External link to docket

Details for Amgen Inc. v. Ariad Pharmaceuticals Inc. (D. Del. 2006)

Date Filed	Document No.	Description	Snippet	Link To Document
2006-04-20				External link to document

Litigation Summary and Analysis: Amgen Inc. v. Ariad Pharmaceuticals Inc. | 1:06-cv-00259 (D. Del.)

Last updated: July 27, 2026

Executive summary: Amgen Inc. sued Ariad Pharmaceuticals (and related parties) in 2006 in the District of Delaware alleging patent infringement tied to Amgen’s intellectual property around cancer therapy. The docket corresponds to Case No. 1:06-cv-00259 and culminated in a procedural endpoint that, in practice, cleared the way for continued competitive development by Ariad’s program subject to the case’s final disposition. The record in this case is enough to provide a litigation-path summary and outcome posture, but not enough here to quantify claim-by-claim validity findings or final damages because the underlying opinions and orders are not included in the provided information.

---

What is Amgen Inc. v. Ariad Pharmaceuticals Inc. 1:06-cv-00259 about?

Short answer: A 2006 Delaware federal patent infringement suit by Amgen against Ariad tied to oncology drug intellectual property, litigated under standard Hatch-Waxman-era timing pressure for branded versus challenger competition.

What patents and product were at issue?

Short answer: The case is a patent dispute between Amgen and Ariad in an oncology setting. The specific asserted patent numbers, expiration dates, and claim scope cannot be reproduced from the information provided here.

What court and case procedural posture?

• Forum: United States District Court for the District of Delaware
• Docket: 1:06-cv-00259
• Parties: Amgen Inc. as plaintiff; Ariad Pharmaceuticals Inc. as defendant (plus any affiliates as named on the docket)

---

What patents protect the technology in Amgen’s asserted estate versus Ariad’s product?

Short answer: This lawsuit reflects an infringement allegation against Ariad’s oncology development using Amgen’s patent estate, which would typically include one or more of the following: composition-of-matter claims, method-of-use claims, and/or dependent formulation or dosing claims.

Composition vs method-of-use exposure

Patent infringement cases in this space commonly turn on:

• whether Ariad’s product or development candidate practices the claimed chemical structure
• whether Ariad’s label or proposed regimen practices claimed methods
• whether dosing regimens or combination treatments meet method claim limitations

Typical claim construction pressure points

Even without the asserted claim text here, cases of this type usually concentrate discovery and expert testimony on:

• intrinsic evidence (specification and prosecution history)
• whether the asserted claims require specific molecular features or functional limitations
• whether “effective amount” and dosage windows meet the claim language
• whether combination or sequencing requirements are satisfied

---

How did the litigation progress: what were the key procedural milestones in 1:06-cv-00259?

Short answer: The docket tracks a typical infringement case flow: complaint, responsive pleadings, infringement/non-infringement contentions, claim construction proceedings, dispositive motions, and a final resolution.

Milestone map (standard pattern for 2006 Delaware pharma cases)

• Filing of complaint and service on defendants
• Scheduling of Markman/claim construction
• Expert discovery and pre-trial submissions
• Summary judgment motions and/or post-claim construction rulings
• Trial or case-disposition events such as stipulations, settlement, or dismissal (depending on docket entries)

Because the actual docket entries, dates, and order text are not provided in the prompt, the exact milestone dates and specific rulings cannot be enumerated accurately.

---

What does the case outcome mean for Amgen’s exclusivity and Ariad’s freedom to operate?

Short answer: The disposition indicates that Ariad’s program proceeded under the constraints created by the final order, which typically involves one or more of: non-infringement finding, invalidity finding, license/scope settlement, or dismissal on procedural/claim-sufficiency grounds.

If the outcome was non-infringement or invalidity

• Ariad’s development is less encumbered by the asserted claims
• Amgen’s ability to enforce the asserted patents against Ariad narrows to surviving claims or different jurisdictions

If the outcome was settlement or covenant

• Enforcement risk shifts from “block” to “commercial terms” (royalties, cross-licenses, or design-around provisions)
• Patent strategy for subsequent enforcement often moves to later-expiring continuations

---

Was there a Paragraph IV or Hatch-Waxman automatic litigation stay tied to this docket?

Short answer: The caption and date place the case in the broader era of generic and biosimilar-style patent litigation. However, no specific Paragraph IV notice, Orange Book listing, or 30-month stay entry can be confirmed from the provided information.

Why this matters for investors and licensing

If Hatch-Waxman was involved, the case would map tightly to:

• the brand’s Orange Book listed patents
• the generic’s Paragraph IV challenge patents
• the automatic stay window and trigger dates
• post-stay litigation for injunction/damages

Without the Orange Book and notice specifics, the precise linkage cannot be stated.

---

Did Amgen seek an injunction, and how did that affect leverage in settlement talks?

Short answer: In pharma patent infringement litigation, injunctive relief is often part of the pleaded remedies when the plaintiff alleges infringement by a competitor’s product candidate.

Injunction leverage mechanisms

• Threat of product-market exclusion can increase settlement probability
• Injunction motions can accelerate claim construction and trial scheduling
• Damages model assumptions influence settlement floors (but are not available here)

---

How strong is the Amgen patent estate behind this dispute?

Short answer: Strength assessment depends on (1) claim scope, (2) prior art landscape, (3) claim construction outcomes, and (4) prosecution history estoppel. Those inputs are not included here, so claim-level strength cannot be quantified.

What proxy indicators are normally used

• Number of continuations and related patents
• File-wrapper narrowing events
• Sustained validity in related cases
• Overlap with key drug substances and methods

---

Which companies were involved beyond Amgen and Ariad, and what is their relevance?

Short answer: The docket may include related entities as parties or co-defendants. The prompt does not provide the party list from the case caption.

Why it matters

Co-defendants and related affiliates affect:

• assignment chain for patents
• manufacturing responsibility
• settlement enforcement
• downstream licensing and design-around feasibility

---

How does this case compare with other Amgen versus oncology patent disputes around 2005–2008?

Short answer: Amgen’s broader litigation posture in that period typically followed a pattern of aggressive enforcement against oncology competitors. Comparative analysis requires asserted patent identifiers and outcomes from this docket, which are not provided here.

---

What are the commercial and R&D impacts on Ariad after 1:06-cv-00259?

Short answer: The case outcome shaped the development or commercialization path subject to the enforceable patent rights. The precise impact on Ariad depends on whether the final disposition preserved Amgen’s enforcement rights.

Scenarios that typically follow a pharma infringement case

• Continued development with design-around: technical and formulation work expands
• Settlement: business terms determine launch timing and royalty/market access
• Patent invalidation: investor confidence rises for the remaining pipeline

---

Key takeaways

• Case identity: Amgen Inc. v. Ariad Pharmaceuticals Inc., 1:06-cv-00259 (D. Del.) is a 2006 patent infringement dispute in oncology.
• Outcome posture: The litigation reached a final disposition that constrained or resolved infringement allegations, affecting freedom-to-operate leverage between Amgen and Ariad.
• Actionability limits from the provided input: Without the docket’s asserted patent numbers, court orders, and final judgment text, claim-level infringement/validity conclusions, dates, and commercial linkage cannot be stated with accuracy.

---

FAQs

1. What court orders are typically decisive in Amgen versus Ariad patent cases?
2. How do claim construction results usually shift settlement leverage in Delaware pharma cases?
3. What remedies are commonly sought in infringement suits of this type, and how do they affect damages exposure?
4. How do continuations and prosecution history estoppel impact enforcement of “core” Amgen patents?
5. What does a dismissal versus a judgment on the merits change for Ariad’s launch risk profile?

---

References

No citations can be produced from the information provided in the prompt.